Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Effects of Radioiodine Therapy on the Natural History of Graves' Ophtalmopathy

Cover Page

Abstract


21 patients with Graves’ disease and Graves’ ophthalmopathy (GO) received radioiodine treatment (RIT). Before 131-I therapy in all patients GO were non-active and no severe. Six patients not received any treatment before RIT; four patients received orbital radiotherapy and 11 patients received intravenous glucocorticoids. Thyreotoxicosis compensation were achieved by antithyroid medication before RIT. Antithyroid medication was stopped 10 days before RIT. Worsening of GO was seen on 47.7% patients 3 months after RIT, but only 9.5% of patients needed additional treatment GO. GO exacerbation take place in 90% of hypothyroid patients and its compensation reduced the symptoms of activity of GO for 3 months. 42.8% was without any symptoms of activity of GO by 9—12 months after RIT. Treatment of GO before RIT were improved the course of GO after RIT.

Otdelenie radiokhirurgicheskogo lecheniya otkrytymi radionuklidami

Otdelenie radiokhirurgicheskogo lecheniya otkrytymi radionuklidami

Otdelenie radiokhirurgicheskogo lecheniya otkrytymi radionuklidami

Otdelenie radiokhirurgicheskogo lecheniya otkrytymi radionuklidami

  1. Древаль А.В., Цыб А.Ф., Нечаева О.А., Комердус И.В. и др. Эффективность лечения диффузного токсического зоба в зависимости от расчетной терапевтической активности радиоактивного йода // Проблемы эндокринологии. 2007. Т. 53, № 2. С. 45-48.
  2. Древаль А.В., Нечаева О.А., Сафиуллина И.М. и др. Аппроксимация по двумерным МРТ-граммам объема прямых глазодвигательных мышц у больных с эндокринной офтальмопатией // Вестник рентгенологии и радиологии. 2003. № 5. С. 4—9.
  3. Dreval A., Nechaeva O., Bardeeva Y. et al. Methylprednisolon therapy in Graves’ ophthalmopathy // 8th Europ Congress of Endocrinology // Endocrine Abstracts. 2006. V. 11. P. 146.
  4. Dreval A., Nechaeva O., Shestakova T. et al. Estimation of influence radioiodine treatment on course of Graves’ ophthalmopathy 9th Europ Congress of Endocrinology // Endocrine Abstracts. 2007. V. 14. P. 321.
  5. Bahn R.S., Heufelder A.E. Mechanisms of disease: Pathogenesis of Graves’ ophthalmopathy // N. Engl. J. Med. 1993. V. 329. P. 1468—1475.
  6. Bartallena L., Marcocci C., Bogazzi F. et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy // N. Engl. J. Med. 1998. V. 338. P. 73—78.
  7. Bartallena L., Marcocci C., Bogazzi F. et al. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism // N. Engl. J. Med. 1989. V. 321. P. 1349—1352.
  8. Bartallena L., Marcocci C., Pinchera A. Graves’ ophthalmopathy: a preventable diseas? // Eur. J. of Endocrinol. 2002 V. 146. P. 457—461.
  9. Bartallena L., Pinchera A., Marcocci C. Management of Graves’ ophthalmopathy: Reality and Perspectives // Endocrine Reviews. 2000 V. 21, N 2. P. 168—199.
  10. Burch H.B., Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management // Endocr. Rev. 1993. V. 14. P. 747—793.
  11. Kung A.W., Yau C.C., Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole // J. Clin. Endocrinol. Metab. 1994. V. 79. P. 542—546.
  12. Marcocci C., Bruno-Bossio G., Manetti L. The course of Graves’ ophthalmopathy is not influenced by near total thyroidectomy // Clin. Endocr. 1999. V. 51. P. 503—508.
  13. Tallstedt L., Lundell G., Torring O. et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism // N. Engl. J. Med. 1992. V. 326. P. 1733—1738.
  14. Tallstedt L., Lundell G., Blomgren H., Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? // Eur. J. Endocrinol. 1994. V. 130. P. 494—497.
  15. Walsh J.P., Dayan C.M. Radioiodine and thyroid eye disease // BMJ. 1999. V. 319. P. 68—69.
  16. Wiersinga W.M. Preventing Graves’ ophthalmopathy // N. Engl. J. Med. 1998. V. 338. P. 121—122.

Views

Abstract - 686

PDF (Russian) - 800

Cited-By


PlumX


Copyright (c) 2007 ., ., ., ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies